PLoS One:过敏性鼻炎儿科患者的急性鼻窦炎群体研究

2019-02-28 AlexYang MedSci原创

虽然慢性鼻窦炎是过敏性鼻炎的常见并发症,而急性鼻窦炎与过敏性鼻炎之间的联系不清楚。最近,有研究人员利用基于群体的健康研究数据评估了患有过敏性鼻炎儿科患者的急性鼻窦炎发生率。研究包括了新诊断的年龄在5-18岁的过敏性鼻炎患者,并通过性别、年龄和年份指数匹配构建了一个比较群体。研究人员对所有的患者进行了跟踪调查,直到急性鼻窦炎诊断或者跟踪调查结束为止,并利用Cox比例风险模型评估了过敏性鼻炎和急性鼻窦

虽然慢性鼻窦炎是过敏性鼻炎的常见并发症,而急性鼻窦炎与过敏性鼻炎之间的联系不清楚。最近,有研究人员利用基于群体的健康研究数据评估了患有过敏性鼻炎儿科患者的急性鼻窦炎发生率。

研究包括了新诊断的年龄在5-18岁的过敏性鼻炎患者,并通过性别、年龄和年份指数匹配构建了一个比较群体。研究人员对所有的患者进行了跟踪调查,直到急性鼻窦炎诊断或者跟踪调查结束为止,并利用Cox比例风险模型评估了过敏性鼻炎和急性鼻窦炎的相关性。研究包括了43588名儿科患者,55.4%为男性,43.9%的参与者年龄在5.0-7.9岁之间。研究发现,患有过敏性鼻炎的患者比不患有过敏性鼻炎的对照组相比,急性鼻窦炎的风险显著更高(调整后风险比=3.03,95%置信区间=2.89-3.18)。研究人员还在男性和女性儿科患者中观察到了相似的风险比。

最后,研究人员指出,儿科患者中过敏性鼻炎与急性鼻窦炎更高的风险显著相关。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1670990, encodeId=8bd116e0990b1, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Mon Dec 16 09:13:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967032, encodeId=5efb196e03269, content=<a href='/topic/show?id=b31a800321e' target=_blank style='color:#2F92EE;'>#群体研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80032, encryptionId=b31a800321e, topicName=群体研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Sep 03 06:13:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047083, encodeId=9875204e0833b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 05 02:13:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717007, encodeId=b3971e1700732, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Wed Nov 06 16:13:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790325, encodeId=f0f11e90325bf, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 21 02:13:00 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1670990, encodeId=8bd116e0990b1, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Mon Dec 16 09:13:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967032, encodeId=5efb196e03269, content=<a href='/topic/show?id=b31a800321e' target=_blank style='color:#2F92EE;'>#群体研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80032, encryptionId=b31a800321e, topicName=群体研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Sep 03 06:13:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047083, encodeId=9875204e0833b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 05 02:13:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717007, encodeId=b3971e1700732, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Wed Nov 06 16:13:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790325, encodeId=f0f11e90325bf, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 21 02:13:00 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1670990, encodeId=8bd116e0990b1, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Mon Dec 16 09:13:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967032, encodeId=5efb196e03269, content=<a href='/topic/show?id=b31a800321e' target=_blank style='color:#2F92EE;'>#群体研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80032, encryptionId=b31a800321e, topicName=群体研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Sep 03 06:13:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047083, encodeId=9875204e0833b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 05 02:13:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717007, encodeId=b3971e1700732, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Wed Nov 06 16:13:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790325, encodeId=f0f11e90325bf, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 21 02:13:00 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1670990, encodeId=8bd116e0990b1, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Mon Dec 16 09:13:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967032, encodeId=5efb196e03269, content=<a href='/topic/show?id=b31a800321e' target=_blank style='color:#2F92EE;'>#群体研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80032, encryptionId=b31a800321e, topicName=群体研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Sep 03 06:13:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047083, encodeId=9875204e0833b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 05 02:13:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717007, encodeId=b3971e1700732, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Wed Nov 06 16:13:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790325, encodeId=f0f11e90325bf, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 21 02:13:00 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
    2019-11-06 xjy13
  5. [GetPortalCommentsPageByObjectIdResponse(id=1670990, encodeId=8bd116e0990b1, content=<a href='/topic/show?id=0de92811870' target=_blank style='color:#2F92EE;'>#儿科患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28118, encryptionId=0de92811870, topicName=儿科患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e9f26811685, createdName=longqijun257, createdTime=Mon Dec 16 09:13:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1967032, encodeId=5efb196e03269, content=<a href='/topic/show?id=b31a800321e' target=_blank style='color:#2F92EE;'>#群体研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80032, encryptionId=b31a800321e, topicName=群体研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Tue Sep 03 06:13:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047083, encodeId=9875204e0833b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Apr 05 02:13:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717007, encodeId=b3971e1700732, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Wed Nov 06 16:13:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790325, encodeId=f0f11e90325bf, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Fri Jun 21 02:13:00 CST 2019, time=2019-06-21, status=1, ipAttribution=)]

相关资讯

Environ Int:室内外颗粒物和空气污染与学前儿童哮喘、喘息、湿疹和鼻炎相关性分析

最近,有研究人员研究了室内颗粒物质(PM)、室外空气污染和抗生素使用与学龄前儿童哮喘、鼻炎和湿疹之间的关系,并调查了PM与抗生素使用之间的协同作用。研究包括了39782名来自中国7个城市的年龄在3-6岁的儿童。环境温度和空气污染数据来自当地监测站。室内PM来源数据(ETS,烧香或蚊香、以及做饭燃烧的生物质)、抗生素的使用和健康通过父母调查问卷来进行评估,并通过多水平逻辑回归来对相关性进行计算。研究

Pediatr Allergy Immunol:过敏性鼻炎儿童中microRNA-181a和microRNA-155参与了调节性T细胞的分化和功能调控

调控性T细胞(Tregs)在限制气道过敏性炎症和预防对环境过敏原不良Th2响应方面具有核心的作用。最近,有研究人员通过体内和体外试验评估了miR-181a和miR-155在调控Tregs分化和功能方面的作用。研究人员从过敏性鼻炎(AR)儿童的外周血单核细胞(PBMCs)中分离纯化了CD4+和Tregs,并将miR-181a/miR-155 mimics和抑制子转化CD4+和Tregs。通过流式细胞

爱尔兰HSE明确指出脊髓性肌萎缩症患儿的药物过于昂贵

据"爱尔兰时报"上周五的报道,卫生服务执行部(HSE)已明确表示脊柱肌肉萎缩药物Spinraza目前的价格并不符合成本效益。

FDA更新了Chantix(伐尼克兰)的处方信息,数据强调它对16岁及以下儿童无效

美国食品和药品监督管理局(FDA)近日改变了Chantix(伐尼克兰)的处方信息。这些变化规定,不建议将该药物用于16岁或以下的儿科患者,因为其在该人群中的疗效未得到证实。

请不要喂我的孩子吃这些!一口都不行!

有孩子的家庭请注意! 有些成人解馋的零食, 对孩子的健康可能造成威胁! 每年都有很多不当喂食孩子造成的悲剧, 父母应时刻警惕! 提醒身边人:不要给孩子乱喂吃的! 喂食孩子导致的悲剧,太多了! 孩子被哄逗喝酒,智商倒退成1岁

你以为采手指血很简单,其实也是门‘技术活’

我们都知道,采血分为静脉采血、皮肤采血、真空采血。工作中运用最多的主要是前两种,采手指血就是属于皮肤采血,曾被称为毛细血管采血,是采集微动脉、微静脉和毛细血管的混合血,同时含有细胞间质和细胞内液。